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tients will have a large impact on drug expenditures. As the
price of thiotepa continues to rise and alternative regimens
are utilized more frequently, there remains a responsibility
for the practitioner to report and determine the most effec-
tive, safe, and economically responsible pediatric hemato-
poietic stem cell transplant conditioning regimen.Figure 1.542
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Background: Tacrolimus (TAC) remains the backbone of
graft-versus-host disease (GVHD) prophylaxis in allogeneic
hematopoietic stem cell transplantation (HSCT). There is
signiﬁcant variability in the serum concentrations of TAC
attained early post-transplant due to drug interactions
and genomic variation. Whether a relationship exists
between early TAC concentrations and acute GVHD in
reduced-intensity conditioning (RIC) HSCT remains poorly
characterized.
Methods: We aimed to retrospectively evaluate whether
mean weekly TAC concentrations correlate with incidence of
acute GVHD in 120 consecutive patients (pts) undergoing
ﬁrst allogeneic HSCT at the University of Pennsylvania be-
tween January 2009 and January 2014. All pts received a
uniform RIC regimen of ﬂudarabine (120 mg/m2) and
busulfan (6.4 mg/kg), followed by infusion of peripheral-
blood stem cells from either a related (n¼53) or unrelated
(n¼67) donor. All pts received standard GVHD prophylaxis
with oral TAC (0.06 mg/kg/day) beginning day -3 and intra-
venous methotrexate (15 mg/m2 day +1, 10 mg/m2 days +3,
+6, +11). The dose of TAC was adjusted to a target trough of
5e15 ng/mL. The primary endpoint was the incidence of
acute grade 2e4 GVHD. We analyzed mean weekly TAC
concentrations as continuous variables up to 4 weeks post-
HSCT and then classiﬁed pts in tertiles (e.g., week 1: 8.5,
8.5e12;>12 ng/mL). Univariate analyses were performed
using cumulative incidence and Cox regression models.
Multivariate models were constructed using the backward
elimination method.
Results: The mean TAC concentrations (ranges) at 1, 2, 3, and
4 weeks after RIC HSCT were 10.2 (2.8e19.4), 10.6 (3.9e23.9),
12.7 (4.2e24.1), and 11.9 (2.9e29.2) ng/mL, respectively. The
day-180 cumulative incidence of acute grade 2e4 GVHD was
42.5%. In multivariate analysis, week 1 TAC concentration
was an independent predictor of acute grade 2e4 GVHD (HR
0.91; 0.84e0.97; P¼.008). Interestingly, this association was
driven by a lower risk of acute grade 2e4 GVHD in pts with
week 1 TAC concentrations in the upper tertile (>12 ng/mL)(HR 0.47; 0.25e0.88; P¼.02), as shown in Figure 1. Week 1
TAC concentrations were not predictive of relapse, chronic
GVHD, overall survival or non-relapse mortality. In this
cohort, 9 pts (7.5%) developed acute kidney injury (AKI) by
day 14. Week 1 TAC concentrations were higher in pts who
developed AKI compared to those who did not (13.0 vs. 10.0
ng/mL; P¼.01). We did not observe an association between
TAC concentrations at weeks 2, 3, and 4 and clinical
outcomes.
Conclusion: Higher TAC concentrations during the ﬁrst
week after RIC HSCT were associated with signiﬁcantly
reduced risk of acute grade 2e4 GVHD without increasing
risk of relapse. These data highlight the importance of opti-
mizing initial dosing of TAC in RIC HSCT recipients.543
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Background: Optimal dosing andmonitoring of MMF and its
metabolites has been a subject of extensive debate/in-
vestigations in the stem cell transplant literature. Due to a
shorter half-life and lack of enterohepatic recycling, more
frequent and higher dosing of MMF may be required in the
early post-AlloSCT period, particularly in children. [Bhatia/
Cairo et al. BBMT 2010;16(3):333-43.]
Figure 1. K-M probability of grade II-IV and III-IV acute GVHD
Abstracts / Biol Blood Marrow Transplant 21 (2015) S355eS373S370Objective: To determine efﬁcacy of MMF administered q8h
in combination with tacrolimus for acute GVHD prophylaxis
in 39 children and young adult AlloSCT recipients.
Methods: GVHD prophylaxis consisted of tacrolimus 0.03-
0.04 mg/kg/day IVCI on Day -1 or 1st day of conditioning
(target range 10-20 ng/mL) and MMF 900 mg/m2 (max 1.5 g/
dose) or 15 mg/kg (age  18 y or weight  70 kg, max 1.5 g/
dose) IV/PO q8h starting on Day +1. Patients were changed to
PO tacrolimus (1:4 dose conversion IV:PO) as clinically
appropriate post-AlloSCT. GVHD prophylaxis was continued
until Day +180 followed by a taper in patients with non-
malignant disorders. In patients with malignant disorders,
MMF was discontinued on Day +30 or Day +60, followed by a
slow tacrolimus taper starting on Day +60. Mycophenolic
acid (MPA) trough concentrations were obtained if MMF-
induced toxicity was suspected. AGVHD, chronic GVHD
(cGVHD) and overall survival (OS) were determined by
Kaplan-Meier (K-M) method.
Results: 39 patients (mean age 12 years [range 0.1-23.5
years]; 27 male vs 12 female) received myeloablative
(n¼20) and non-myeloablative (n¼19) conditioning for
malignant (n¼28) and non-malignant disorders (n¼11).
Donor sources were: 6/6 MSD (n¼12), 4/6-6/6 UCB
(n¼16), and 9/10 or 10/10 MUD (n¼11). Sixteen/28 pa-
tients with malignant disease were poor risk. Median time
to myeloid and platelet engraftment was 16 and 32 days,
respectively. Probability of grade II-IV aGVHD and grade
III-IV aGVHD was 16.6% (CI95: 1.8-44.7) and 2.9% (CI95: 0-
60.6), respectively (n¼37 evaluable patients).[Figure 1]
Only one patient experienced grade III (liver +gut) aGVHD,
with no patients developing grade IV aGVHD. Probability
of limited + extensive cGVHD (n¼34 evaluable patients)
was 23.6% (CI95: 8.0-50.5).
Nine patients died at a median 198 days post-SCT
(range 109-549). Causes of death included chronic GVHD
(n¼2), acute GVHD (n¼1), TMA (n¼1), viral or fungal
infection (n¼2), relapse (n¼2), and EBV PTLD (n¼1). K-M
probability of 1 year overall survival was 72.5% (CI95: 53.3-
84.9).
Conclusion: Tacrolimus in combinationwith MMF given q8h
as described above are highly effective for aGVHD prophy-
laxis in this heterogeneous group of pediatric and young
adult AlloSCT recipients. The incidence of grade II-IV aGVHD
in the current study appears to be substantially lower than
reported in our previous trial withMMF dosed at 900mg/m2
q6h in a similar group of pediatric and adolescent AlloSCT
recipients (16.6% vs 54.4%).[Bhatia/Cairo et al. BBMT
2010;16(3):333-343]544
Results of the American Society for Blood and Marrow
Transplantation Pharmacy Special Interest Group
Practice Survey e Understanding Today to Meet the Needs
of Tomorrow
Ila Maewal Saunders 1, Amy W. Bryk 2, JoAl Mayor 3,
Rebecca Tombleson 4, Jeffrey Betcher 5, Beth Eddy 6,
Adam Melaragno 7, Jill R. Rhodes 8, Tippu Khan 9,
Susannah Koontz 10. 1 UC San Diego Skaggs School of Pharmacy
& Pharmaceutical Sciences, La Jolla, CA; 2Department of
Pharmacy, The Johns Hopkins Hospital, Baltimore, MD;
3University of Washington Seattle Cancer Care Alliance,
Seattle, WA; 4 Pharmacy, Mofﬁtt Cancer Center, Tampa, FL;
5 Pharmacy, Mayo Clinic Arizona, Phoenix, AZ; 6 University of
Kansas Medical Center, Kansas City, KS; 7 University of
Rochester Medical Center, Rochester, NY; 8 University of
Louisville Hospital / James Graham Brown Cancer Center,
Louisville, KY; 9 Department of Pharmacy, University of North
Carolina, Chapel Hill, NC; 10 Koontz Oncology Consulting LLC,
Houston, TX
The National Marrow Donor Program (NMDP) has estimated
that the number of hematopoietic stem cell transplants
(HSCTs) performed will double by 2015 as compared to 2010.
The NMDP also projects a shortage of physicians, physician
assistants, nurses, nurse practitioners, and pharmacists. In
response to this anticipated shortage, the American Society
for Blood and Marrow Transplantation (ASBMT) Pharmacy
Special Interest Group (SIG) was created in 2012. The ASBMT
Pharmacy SIG recognized the need to engage non-physician
providers in the care of patients and supplement the training
of such practitioners. The ASBMT Pharmacy SIG has priori-
tized the education of these practitioners and has success-
fully developed and implemented the Fundamentals of HSCT
course to address this issue.
Another priority of the ASBMT Pharmacy SIG was to
determine the value of HSCT pharmacists in clinical
practice. Thus, a survey was conducted in January 2014
to collect baseline data of the current ASBMT Pharmacy
SIG make-up and practice patterns. The survey was
distributed to approximately 250 participants and 56
surveys were returned. Of the 56 responders, most
practitioners worked in academic medical centers (91%)
with the majority of centers performing less than 300
HSCTs per year (85%). Most institutions had 3 or fewer
pharmacists dedicated to HSCT services (68%). The
highest level of training and certiﬁcation for the majority
of pharmacists practicing in HSCT was a post-graduate
year 2 oncology pharmacy practice residency (64%) and a
board certiﬁcation in oncology pharmacy (61%), respec-
tively. Though the majority of practitioners spent any-
where from 50-100% of their time dedicated to clinical
activities, only 25% of practitioners had an established
collaborative practice protocol in place. Furthermore,
most HSCT pharmacists spent 20% or less of their time
devoted to teaching, administrative, or research activ-
ities. Many practitioners were involved with pharmacy
organizations and spent time outside of their clinical
duties to work on publications and professional
development.
The results of this survey provide a snapshot of the cur-
rent HSCT pharmacy climate and may be used as a tool to
educate healthcare practitioners on roles and re-
sponsibilities of HSCT pharmacists. These results may also
serve as foundation for the development of HSCT phar-
macist competencies in the future and a framework for
